JP2014530597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530597A5 JP2014530597A5 JP2014530333A JP2014530333A JP2014530597A5 JP 2014530597 A5 JP2014530597 A5 JP 2014530597A5 JP 2014530333 A JP2014530333 A JP 2014530333A JP 2014530333 A JP2014530333 A JP 2014530333A JP 2014530597 A5 JP2014530597 A5 JP 2014530597A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- item
- isolated
- tau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 103
- 150000001875 compounds Chemical class 0.000 claims description 49
- 239000003112 inhibitor Substances 0.000 claims description 40
- 208000034799 Tauopathies Diseases 0.000 claims description 34
- 208000024827 Alzheimer disease Diseases 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 24
- 230000001575 pathological effect Effects 0.000 claims description 22
- 230000002776 aggregation Effects 0.000 claims description 19
- 238000004220 aggregation Methods 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 9
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 9
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 9
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 9
- 239000003524 antilipemic agent Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 9
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 9
- 108060006633 protein kinase Proteins 0.000 claims description 9
- 229910052723 transition metal Inorganic materials 0.000 claims description 9
- 150000003624 transition metals Chemical class 0.000 claims description 9
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 8
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 8
- 238000007913 intrathecal administration Methods 0.000 claims description 7
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 241001260012 Bursa Species 0.000 claims description 4
- 108700012434 CCL3 Proteins 0.000 claims description 4
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 4
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102000009843 Thyroglobulin Human genes 0.000 claims description 4
- 108010034949 Thyroglobulin Proteins 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000007914 intraventricular administration Methods 0.000 claims description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 4
- 239000005022 packaging material Substances 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 229960002175 thyroglobulin Drugs 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 238000002967 competitive immunoassay Methods 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 230000036963 noncompetitive effect Effects 0.000 claims 1
- 231100000915 pathological change Toxicity 0.000 claims 1
- 230000036285 pathological change Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 description 87
- 108010026424 tau Proteins Proteins 0.000 description 87
- 108090000765 processed proteins & peptides Proteins 0.000 description 66
- 239000002671 adjuvant Substances 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 208000028698 Cognitive impairment Diseases 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000003920 cognitive function Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 230000007659 motor function Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940016590 sarkosyl Drugs 0.000 description 4
- 108700004121 sarkosyl Proteins 0.000 description 4
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 229940122777 Tau aggregation inhibitor Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003188 neurobehavioral effect Effects 0.000 description 2
- -1 phospho group Chemical group 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229940121773 Secretase inhibitor Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161536339P | 2011-09-19 | 2011-09-19 | |
| US61/536,339 | 2011-09-19 | ||
| US201261653115P | 2012-05-30 | 2012-05-30 | |
| US61/653,115 | 2012-05-30 | ||
| PCT/IB2012/002246 WO2013041962A1 (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230258A Division JP6360869B2 (ja) | 2011-09-19 | 2016-11-28 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530597A JP2014530597A (ja) | 2014-11-20 |
| JP2014530597A5 true JP2014530597A5 (OSRAM) | 2015-11-05 |
| JP6253583B2 JP6253583B2 (ja) | 2017-12-27 |
Family
ID=47216372
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530333A Active JP6253583B2 (ja) | 2011-09-19 | 2012-09-14 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2016230258A Active JP6360869B2 (ja) | 2011-09-19 | 2016-11-28 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2017033138A Active JP6286590B2 (ja) | 2011-09-19 | 2017-02-24 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018059946A Active JP6499345B2 (ja) | 2011-09-19 | 2018-03-27 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018132100A Active JP6637124B2 (ja) | 2011-09-19 | 2018-07-12 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2019228943A Active JP6950981B2 (ja) | 2011-09-19 | 2019-12-19 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2021150176A Active JP7182316B2 (ja) | 2011-09-19 | 2021-09-15 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230258A Active JP6360869B2 (ja) | 2011-09-19 | 2016-11-28 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2017033138A Active JP6286590B2 (ja) | 2011-09-19 | 2017-02-24 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018059946A Active JP6499345B2 (ja) | 2011-09-19 | 2018-03-27 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018132100A Active JP6637124B2 (ja) | 2011-09-19 | 2018-07-12 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2019228943A Active JP6950981B2 (ja) | 2011-09-19 | 2019-12-19 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2021150176A Active JP7182316B2 (ja) | 2011-09-19 | 2021-09-15 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9518101B2 (OSRAM) |
| EP (2) | EP3275461A1 (OSRAM) |
| JP (7) | JP6253583B2 (OSRAM) |
| KR (3) | KR102130439B1 (OSRAM) |
| CN (2) | CN109265543B (OSRAM) |
| AU (3) | AU2012311234B2 (OSRAM) |
| BR (1) | BR112014006376B1 (OSRAM) |
| CA (1) | CA2848346A1 (OSRAM) |
| CL (3) | CL2014000679A1 (OSRAM) |
| CY (1) | CY1119792T1 (OSRAM) |
| DK (1) | DK2758433T3 (OSRAM) |
| ES (1) | ES2656442T3 (OSRAM) |
| HR (1) | HRP20180083T8 (OSRAM) |
| HU (1) | HUE036177T2 (OSRAM) |
| IL (4) | IL231201B (OSRAM) |
| LT (1) | LT2758433T (OSRAM) |
| ME (1) | ME03008B (OSRAM) |
| MX (2) | MX347505B (OSRAM) |
| MY (1) | MY183989A (OSRAM) |
| PL (1) | PL2758433T3 (OSRAM) |
| PT (1) | PT2758433T (OSRAM) |
| RS (1) | RS56852B1 (OSRAM) |
| RU (2) | RU2645259C2 (OSRAM) |
| SG (4) | SG10201912964PA (OSRAM) |
| SI (1) | SI2758433T1 (OSRAM) |
| SM (1) | SMT201800109T1 (OSRAM) |
| TR (1) | TR201800669T4 (OSRAM) |
| UA (2) | UA123390C2 (OSRAM) |
| WO (1) | WO2013041962A1 (OSRAM) |
| ZA (1) | ZA201401333B (OSRAM) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EP3838921A3 (en) | 2012-07-03 | 2021-09-01 | Washington University | Antibodies to tau |
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| MX384909B (es) * | 2013-11-27 | 2025-03-14 | Ipierian Inc | Un anticuerpo anti-tau para usarse al tratar una tauopatía. |
| US10981953B2 (en) * | 2013-12-26 | 2021-04-20 | Toagosei Co, Ltd. | Method for promoting expression of calreticulin, and synthetic peptide for use in method for promoting expression of calreticulin |
| US10400018B2 (en) | 2014-02-14 | 2019-09-03 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| AU2015279086B2 (en) | 2014-06-26 | 2021-01-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| EP3760235A1 (en) | 2014-09-30 | 2021-01-06 | Washington University | Tau kinetic measurements |
| WO2016077689A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| SMT202100055T1 (it) * | 2014-11-19 | 2021-03-15 | Axon Neuroscience Se | Anticorpi tau umanizzati nella malattia di alzheimer |
| JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| PL3303386T3 (pl) | 2015-06-05 | 2025-03-03 | Genentech, Inc. | Przeciwciała anty-tau i sposoby zastosowania |
| AU2016289753C1 (en) | 2015-07-06 | 2021-08-05 | UCB Biopharma SRL | Tau-binding antibodies |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| GB201518675D0 (en) * | 2015-10-21 | 2015-12-02 | Cellcap Technologies Ltd | Detection of structural forms of proteins |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3452508A1 (en) * | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| KR101997319B1 (ko) * | 2016-06-21 | 2019-07-08 | 전남대학교산학협력단 | 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용 |
| WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
| FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TWI787219B (zh) | 2016-12-07 | 2022-12-21 | 美商建南德克公司 | 抗-ｔａｕ抗體及使用方法 |
| KR102032314B1 (ko) * | 2016-12-21 | 2019-10-16 | 주식회사 아델 | 변이된 타우 단백질 단편 및 이의 용도 |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| WO2018178077A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| WO2018195376A1 (en) * | 2017-04-21 | 2018-10-25 | Ohio University | Peptide-based inhibitors of mark family proteins |
| MX2019013045A (es) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| JP7029718B2 (ja) * | 2017-07-31 | 2022-03-04 | 国立研究開発法人量子科学技術研究開発機構 | リン酸化タウタンパク質の測定方法 |
| JP6979533B2 (ja) | 2017-10-02 | 2021-12-15 | ブラックソーン セラピューティクス インコーポレイテッド | 対象における神経行動学的表現型を検知、診断、予測、予知、または処置するための方法及びツール |
| PE20210115A1 (es) | 2017-10-16 | 2021-01-19 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
| TW202333768A (zh) | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| JP2021508673A (ja) * | 2017-10-27 | 2021-03-11 | ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ | タウペプチド免疫原構築物 |
| WO2019120527A1 (en) * | 2017-12-20 | 2019-06-27 | Michael Heneka | Novel means and methods for treating neurodegenerative diseases |
| CN111918875A (zh) | 2018-03-11 | 2020-11-10 | 库罗什·沙帕桑 | 构象-特异性的抗神经毒性tau蛋白的抗体 |
| AU2019244481A1 (en) | 2018-03-28 | 2020-10-01 | Axon Neuroscience Se | Antibody-based methods of detecting and treating Alzheimer's disease |
| RU2679080C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| RU2679059C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| AU2019262220B2 (en) * | 2018-05-03 | 2025-10-16 | Washington University | Methods of diagnosing and treating based on site-specific tau phosphorylation |
| US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
| KR102585973B1 (ko) * | 2018-07-03 | 2023-10-10 | 에프. 호프만-라 로슈 아게 | 타우 발현을 조절하기 위한 올리고뉴클레오티드 |
| JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
| UA129124C2 (uk) * | 2018-11-08 | 2025-01-22 | Протена Біосайєнсіс Лімітед | Антитіла, що розпізнають тау |
| WO2020106598A1 (en) * | 2018-11-19 | 2020-05-28 | The Board Of Regents Of The University Of Texas System | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies |
| EP3894438A1 (en) * | 2018-12-13 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JOP20210211A1 (ar) | 2019-02-08 | 2023-01-30 | Janssen Pharmaceuticals Inc | طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر |
| AU2020219374A1 (en) * | 2019-02-08 | 2021-07-01 | Prothena Biosciences Limited | Antibodies recognizing tau |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JP2022526334A (ja) * | 2019-03-25 | 2022-05-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 新たなタウ種を標的化することによるタウオパチー障害の処置の方法 |
| AU2020262899A1 (en) * | 2019-04-24 | 2021-11-18 | Ac Immune S.A. | Heterologous administration of tau vaccines |
| CN120559249A (zh) * | 2019-05-31 | 2025-08-29 | 伊莱利利公司 | 靶向人tau的化合物和方法 |
| GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| EP4007773A1 (en) * | 2019-08-06 | 2022-06-08 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| CA3147548A1 (en) * | 2019-08-13 | 2021-02-18 | Randall Bateman | Methods to detect mtbr tau isoforms and use thereof |
| WO2021029181A1 (ja) * | 2019-08-15 | 2021-02-18 | 学校法人東京医科大学 | Ｃｌｓｐ阻害物質による影響を受けないｃｌｓｐ誘導体及びｃｌｓｐ活性の増強／保護剤 |
| AU2020345110A1 (en) * | 2019-09-09 | 2022-03-24 | Axon Neuroscience Se | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| BR112022004326A2 (pt) | 2019-09-10 | 2022-08-23 | Univ Washington | Ensaio de base sanguínea para diagnóstico e tratamento com base em fosforilação de tau específica do sítio |
| US20220372123A1 (en) * | 2019-10-22 | 2022-11-24 | Biogen Ma Inc. | Anti-beta-amyloid antibody for treating alzheimer's disease |
| IL270800A (en) * | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
| CN110841059A (zh) * | 2019-12-03 | 2020-02-28 | 南通大学 | 老年性痴呆小鼠模型的制备方法 |
| MX2022009607A (es) * | 2020-02-05 | 2022-09-02 | Sumitomo Pharma Co Ltd | Agente de determinacion y metodo de determinacion de taupatia y enfermedades relacionadas con la demencia. |
| AU2021276401A1 (en) * | 2020-05-19 | 2022-12-15 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of Alzheimer's disease |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| KR20230080397A (ko) * | 2020-08-07 | 2023-06-07 | 오타이르 프로테나 리미티드 | 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신 |
| CA3188458A1 (en) * | 2020-08-07 | 2022-02-10 | Robin Barbour | Tau vaccine for the treatment of alzheimer's disease |
| CA3203308A1 (en) | 2020-11-30 | 2022-06-02 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
| WO2022133324A1 (en) * | 2020-12-18 | 2022-06-23 | Sangamo Therapeutics, Inc. | Improved pharmaceutical compositions containing adeno-associated viral vector |
| JP2024506391A (ja) * | 2021-02-14 | 2024-02-13 | プロシーナ バイオサイエンシーズ リミテッド | タウを認識する抗体の使用方法 |
| WO2022176959A1 (en) * | 2021-02-19 | 2022-08-25 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| EP4297868A4 (en) | 2021-02-23 | 2025-01-08 | Hoth Therapeutics, Inc. | USE OF APREPITANT TO TREAT ALZHEIMER'S |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| CN113430230A (zh) * | 2021-06-24 | 2021-09-24 | 南通大学 | tau截断体蛋白在诱导tau病理聚集中的应用 |
| EP4413366A4 (en) * | 2021-10-08 | 2025-09-10 | Tiberias Tech Hk Limited | TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17 |
| CN113861441A (zh) * | 2021-10-28 | 2021-12-31 | 南开大学 | 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN116554342A (zh) * | 2022-01-29 | 2023-08-08 | 元本(珠海横琴)生物科技有限公司 | 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株 |
| AU2023223603A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2025019332A1 (en) * | 2023-07-14 | 2025-01-23 | Alzpath, Inc. | Methods for remote blood collection, extraction and analysis of neuro biomarkers |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
| CN117624354B (zh) * | 2023-11-30 | 2024-07-12 | 无锡傲锐东源生物科技有限公司 | 一种抗人乙酰化tau281兔单克隆抗体及其应用 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| FI895955A7 (fi) | 1988-04-15 | 1989-12-13 | Protein Design Labs Inc | Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU638762B2 (en) | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| DE69233767D1 (de) * | 1991-12-06 | 2009-09-17 | Max Planck Gesellschaft | Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| JPH09501936A (ja) | 1993-08-26 | 1997-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置 |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| NZ295371A (en) * | 1994-10-28 | 1998-11-25 | Max Planck Gesellschaft | Protein kinase npk-10, a composition for treating alzheimers disease and cancer and diagnostic kits |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5643207A (en) | 1995-04-28 | 1997-07-01 | Medtronic, Inc. | Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| EP1281718A3 (en) | 1995-11-10 | 2005-01-19 | ELAN CORPORATION, Plc | Peptides which enhance transport across tissues |
| US5820589A (en) | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| US6198966B1 (en) | 1999-02-26 | 2001-03-06 | Medtronic, Inc. | Recirculating implantable drug delivery system |
| JP3383618B2 (ja) | 1999-08-18 | 2003-03-04 | 松下電器産業株式会社 | 移動体通信端末装置及び受信強度検出方法 |
| WO2001018544A1 (en) * | 1999-09-09 | 2001-03-15 | Mcgill University | Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases |
| EP1214598B1 (en) | 1999-09-09 | 2006-05-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening for inhibitors of "paired helical filaments" |
| US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| ATE345812T1 (de) | 2001-09-03 | 2006-12-15 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Antigen-mimotope und vakzine gegen krebserkrankungen |
| TWI226905B (en) | 2001-10-19 | 2005-01-21 | Bioware Technology Co Ltd | Low pressure-accelerated particle gene gun |
| DK1521774T3 (da) * | 2002-07-12 | 2008-10-27 | Axon Neuroscience | Trunkerede Tau-proteiner |
| CA2487528A1 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| EP1516930A1 (en) | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Cellular model of tauopathies for lead identification and drug discovery |
| MXPA06003886A (es) | 2003-10-08 | 2006-08-11 | Ebioscience | Reactivos de enlace de inmunoglobulina naturales y metodos de fabricacion y uso de los mismos. |
| CN1721437A (zh) * | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8377875B2 (en) | 2007-01-11 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Therapeutics based on tau/microtubule dynamics |
| US8106015B2 (en) * | 2007-04-20 | 2012-01-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
| EP2171089B1 (en) | 2007-06-25 | 2014-01-22 | Universität Duisburg-Essen | Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2440234A4 (en) * | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS |
| WO2011026031A1 (en) * | 2009-08-28 | 2011-03-03 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
| WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| EP2496594B1 (en) | 2009-11-06 | 2018-01-17 | The J. David Gladstone Institutes | Methods and compositions for modulating tau levels |
| KR102177195B1 (ko) * | 2009-11-19 | 2020-11-11 | 솔리스 바이오다인 오위 | 폴리펩티드 안정성 및 활성을 증가시키는 조성물 및 관련된 방법 |
| CL2010000019A1 (es) * | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2012
- 2012-09-14 BR BR112014006376-1A patent/BR112014006376B1/pt active IP Right Grant
- 2012-09-14 MY MYPI2014000803A patent/MY183989A/en unknown
- 2012-09-14 LT LTEP12788639.8T patent/LT2758433T/lt unknown
- 2012-09-14 UA UAA201706478A patent/UA123390C2/uk unknown
- 2012-09-14 KR KR1020147010525A patent/KR102130439B1/ko active Active
- 2012-09-14 MX MX2014003357A patent/MX347505B/es active IP Right Grant
- 2012-09-14 ME MEP-2018-18A patent/ME03008B/me unknown
- 2012-09-14 KR KR1020217024024A patent/KR20210099167A/ko not_active Ceased
- 2012-09-14 EP EP17190247.1A patent/EP3275461A1/en active Pending
- 2012-09-14 CA CA2848346A patent/CA2848346A1/en not_active Abandoned
- 2012-09-14 SG SG10201912964PA patent/SG10201912964PA/en unknown
- 2012-09-14 MX MX2017005573A patent/MX391157B/es unknown
- 2012-09-14 JP JP2014530333A patent/JP6253583B2/ja active Active
- 2012-09-14 KR KR1020207018712A patent/KR102285743B1/ko active Active
- 2012-09-14 SG SG10201703771WA patent/SG10201703771WA/en unknown
- 2012-09-14 HU HUE12788639A patent/HUE036177T2/hu unknown
- 2012-09-14 PT PT127886398T patent/PT2758433T/pt unknown
- 2012-09-14 RU RU2014115481A patent/RU2645259C2/ru active
- 2012-09-14 PL PL12788639T patent/PL2758433T3/pl unknown
- 2012-09-14 CN CN201810662577.7A patent/CN109265543B/zh active Active
- 2012-09-14 AU AU2012311234A patent/AU2012311234B2/en active Active
- 2012-09-14 SM SM20180109T patent/SMT201800109T1/it unknown
- 2012-09-14 TR TR2018/00669T patent/TR201800669T4/tr unknown
- 2012-09-14 SG SG11201400125RA patent/SG11201400125RA/en unknown
- 2012-09-14 WO PCT/IB2012/002246 patent/WO2013041962A1/en not_active Ceased
- 2012-09-14 HR HRP20180083TT patent/HRP20180083T8/hr unknown
- 2012-09-14 RS RS20180054A patent/RS56852B1/sr unknown
- 2012-09-14 UA UAA201404170A patent/UA115657C2/uk unknown
- 2012-09-14 EP EP12788639.8A patent/EP2758433B1/en active Active
- 2012-09-14 RU RU2018102103A patent/RU2018102103A/ru unknown
- 2012-09-14 ES ES12788639.8T patent/ES2656442T3/es active Active
- 2012-09-14 SG SG10201912955PA patent/SG10201912955PA/en unknown
- 2012-09-14 SI SI201231187T patent/SI2758433T1/en unknown
- 2012-09-14 DK DK12788639.8T patent/DK2758433T3/en active
- 2012-09-14 CN CN201280056856.XA patent/CN104185640B/zh active Active
- 2012-09-14 US US14/345,561 patent/US9518101B2/en active Active
-
2014
- 2014-02-21 ZA ZA2014/01333A patent/ZA201401333B/en unknown
- 2014-02-27 IL IL231201A patent/IL231201B/en active IP Right Grant
- 2014-03-19 CL CL2014000679A patent/CL2014000679A1/es unknown
-
2015
- 2015-05-14 CL CL2015001314A patent/CL2015001314A1/es unknown
-
2016
- 2016-01-27 CL CL2016000215A patent/CL2016000215A1/es unknown
- 2016-11-03 US US15/342,629 patent/US9828421B2/en active Active
- 2016-11-28 JP JP2016230258A patent/JP6360869B2/ja active Active
-
2017
- 2017-02-24 JP JP2017033138A patent/JP6286590B2/ja active Active
- 2017-05-19 US US15/599,685 patent/US9845352B2/en active Active
- 2017-11-02 US US15/801,341 patent/US11098106B2/en active Active
- 2017-12-07 AU AU2017272259A patent/AU2017272259B2/en active Active
-
2018
- 2018-01-17 CY CY20181100058T patent/CY1119792T1/el unknown
- 2018-03-27 JP JP2018059946A patent/JP6499345B2/ja active Active
- 2018-06-03 IL IL259775A patent/IL259775B/en active IP Right Grant
- 2018-07-12 JP JP2018132100A patent/JP6637124B2/ja active Active
-
2019
- 2019-12-19 JP JP2019228943A patent/JP6950981B2/ja active Active
-
2020
- 2020-01-29 AU AU2020200624A patent/AU2020200624B2/en active Active
- 2020-05-04 IL IL274440A patent/IL274440B/en unknown
-
2021
- 2021-07-27 US US17/443,779 patent/US12404322B2/en active Active
- 2021-09-15 JP JP2021150176A patent/JP7182316B2/ja active Active
- 2021-11-02 IL IL287794A patent/IL287794A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530597A5 (OSRAM) | ||
| RU2014115481A (ru) | Терапия и диагностика на основе белков тау-опосредуемой патологии при болезни альцгеймера | |
| JP7532571B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| US12145988B2 (en) | Anti-TREM-2 agonist antibodies | |
| US8323651B2 (en) | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | |
| EP3534937B1 (en) | Antibodies to pyroglutamate amyloid-beta and uses thereof | |
| CA3007000C (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| CN105283196B (zh) | 用于产生和使用构象-特异性抗体的方法和组合物 | |
| JP2022058369A (ja) | アルツハイマー病治療方法 | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| AU2009303453B2 (en) | Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis | |
| CN112601550B (zh) | 抗-乙型淀粉样蛋白抗体及其用途 | |
| KR20250150001A (ko) | 항-Aβ 항체를 이용한 신경계 장애의 치료 방법 | |
| HK1178913A (en) | ANTI-Aβ ANTIBODIES AND THEIR USE |